All In Biotech

Drug Trial Radar · NCT07710248

SG301-SC Injection Safety Study in Subjects With Primary ITP Patients

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Safety and Efficacy of SG301 SC Injection in Patients With Primary Immune Thrombocytopenia

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

May 17, 2027

Study completion May 17, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. The primary objective is to evaluate the safety and efficacy of SG301 SC Injection in participants with ITP, while the secondary objectives are to assess the pharmacokinetic, pharmacodynamic and immunogenicity profiles of SG301 SC Injection in ITP participants. A total of 60 ITP participants are planned to be enrolled in this study and randomly assigned at a 1:1:1 ratio to the low dose group, high dose group and placebo group, with approximately 20 participants per group. All participants enrolled in this study may receive concomitant background therapies at stable doses for at least 4 weeks prior to the first study drug administration, and is expected to be maintained throughout the study period.

Conditions

  • Primary Immune Thrombocytopenia

Interventions

  • low dose groupDrug

    SG301 SC weekly for a total of 8 doses, subcutaneous injection

  • high dose groupDrug

    SG301 SC weekly for a total of 8 doses , subcutaneous injection

  • Placebo groupDrug

    SG301 SC Placebo weekly for a total of 8 doses, subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: up to 24 weeks
  2. ORRTime frame: at Week 8 of treatment

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China · Not yet recruiting

  • Yulin Red Cross Hospital

    Yulin, Guangxi, China · Recruiting

  • Hebei University Affiliated Hospital

    Baoding, Hebei, China · Not yet recruiting

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China · Not yet recruiting

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, Hebei, China · Recruiting

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • Pingdingshan First People's Hospital

    Pingdingshan, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhenzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Not yet recruiting

  • Siping Central People's Hospital

    Siping, Jilin, China · Recruiting

  • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)

    Jinan, Shandong, China · Recruiting

  • Jining No.1 People's Hospital

    Jining, Shandong, China · Recruiting

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China · Recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xian, Shanxi, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

  • Yunnan Provincial First People's Hospital

    Kunming, Yunnan, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.